Becton Dickinson FACSAria Flow Cytometer

Becton Dickinson FACSAria 流式细胞仪

• 批准号: 6877369
• 负责人: LELAND H HARTWELL
• 金额: $ 47.89万
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-02-15 至 2006-02-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6877369
• 关键词: biomedical equipment purchase; cell sorting; flow cytometry

DESCRIPTION (provided by applicant): The Flow Cytometry Facility of the Fred Hutchinson Cancer Research Center (FHCRC) respectfully requests funds to acquire a Becton Dickinson FACSAria cell sorter to replace an eleven-year-old Becton Dickinson FACS Vantage SE cell sorter. The FACSAria will be equipped with 15 parameter detection, Automated Cell Deposition Unit (ACDU), computer, Aerosol Management System, and table. While the FACS Vantage has been a dependable cell sorter, its limitations have impeded its ability to meet the needs of today's more advanced experimentation. The core user group for the FACSAria consists of members from the major scientific divisions within the FHCRC. As will be noted in the research plan, many of the projects from our varied client base will benefit from the added capabilities of this instrument. These projects will see an immediate enhancement in the research currently being performed due to the FACSAria's heightened sensitivity, its 15-parameter detection, higher throughput, and its ability to sort four populations simultaneously. With the fixed alignment and canned cleaning functions inherent in the instruments design, the FACSAria will benefit the overall functionality of the core facility. The Flow Cytometry facility has operated as a shared resource at the FHCRC for 26 years. It has grown to be an integral part of the scientific research supporting 79 laboratories from 13 programs within the cancer center. With the broad base of applications being run on the facility's cell sorters, the FACSAria would benefit most applications within this shared environment. The FACSAria will address both immediate and future needs of our user community, supporting NIH funded research at the FHCRC.

描述（由申请人提供）：Fred Hutchinson癌症研究中心（FHCRC）的流式细胞仪设施恭敬地要求资金购买Becton Dickinson Facsaria细胞分子分子，以取代Eleven年轻的Becton Dickinson Facs Vantage Vantage Vantage SE Soter。 FACSARIA将配备15个参数检测，自动细胞沉积单元（ACDU），计算机，气溶胶管理系统和表。尽管FACS Vantage一直是一个可靠的细胞分辨率，但其局限性阻碍了其满足当今更高级实验的需求的能力。 FACSARIA的核心用户组由FHCRC中主要科学部门的成员组成。正如研究计划中将指出的那样，我们各种客户群的许多项目将受益于该工具的附加功能。由于FACSARIA的敏感性提高，其15参数检测，更高的吞吐量以及同时分类四个人群的能力，这些项目将立即进行目前正在进行的研究的立即增强。凭借仪器设计中固有的固定对齐和罐头清洁功能，Facsaria将使核心设施的整体功能受益。 流式细胞仪设施已在FHCRC的共享资源运行了26年。它已成为科学研究的组成部分，该科学研究支持癌症中心13个计划的79个实验室。随着该设施的细胞分类器的广泛应用程序的广泛基础，FACSARIA将受益于此共享环境中的大多数应用程序。 Facsaria将满足用户社区的直接和未来需求，并支持NIH资助的FHCRC研究。